Literature DB >> 16357456

Type 1 diabetes mellitus and drug-resistant epilepsy: presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid.

Takanobu Yoshimoto1, Masaru Doi, Nozomi Fukai, Hajime Izumiyama, Takehiko Wago, Isao Minami, Isao Uchimura, Yukio Hirata.   

Abstract

A 55-year-old man who was diagnosed as having type 1 diabetes mellitus (DM) at the age of 50 years was started on insulin therapy. At 54 years old of age, he suddenly developed complex partial seizures, which frequently occurred despite intensive anti-epileptic drug therapy. Neurological examination on admission revealed hyporeflexia in bilateral upper and lower extremities without any muscle rigidity, painful spasm or cerebellar ataxia. Laboratory examination showed poor glycemic control with increased glycated hemoglobin levels. Positive anti-thyroglobulin antibodies and anti-thyroid peroxidase (TPO) antibodies and slight elevation of TSH levels are consistent with subclinical hypothyroidism due to Hashimoto's thyroiditis. A high titer of anti-glutamic acid decarboxylase (GAD) antibodies was detected in the patient's serum and cerebrospinal fluid (CSF). Electroencephalography showed temporal spikes, consistent with complex partial seizure. This is a very rare case presenting with concomitant type 1 diabetes and drug-resistant epilepsy associated with high titers of circulating and CSF anti-GAD antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357456     DOI: 10.2169/internalmedicine.44.1174

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies.

Authors:  Esther Ganelin-Cohen; Dalit Modan-Moses; Rina Hemi; Hannah Kanety; Bruria Ben-Zeev; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2015-12-29       Impact factor: 4.866

2.  Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.

Authors:  Hazael Flores-Cantu; Carlos R Camara-Lemarroy; Hector J Calderon-Hernandez; Maria A Zapata-Rivera; Jesus Z Villareal-Perez; Hector J Villareal-Velazquez
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

3.  Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep.

Authors:  Maria Giuseppina Baglietto; Maria Margherita Mancardi; Alessandro Giannattasio; Nicola Minuto; Andrea Rossi; Giuseppe Capovilla; Edvige Veneselli; Renata Lorini; Giuseppe d'Annunzio
Journal:  Neurol Sci       Date:  2009-08-15       Impact factor: 3.307

Review 4.  Altered GABA signaling in early life epilepsies.

Authors:  Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neural Plast       Date:  2011-07-31       Impact factor: 3.599

5.  Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.

Authors:  So Yamamura; Tomoyasu Fukui; Yusaku Mori; Toshiyuki Hayashi; Takeshi Yamamoto; Makoto Ohara; Ayako Fukase; Hiroto Sasamori; Tetsuro Kobayashi; Tsutomu Hirano
Journal:  J Diabetes Investig       Date:  2019-04-19       Impact factor: 4.232

6.  GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.

Authors:  Suvi Liimatainen; Jerome Honnorat; Sean J Pittock; Andrew McKeon; Mario Manto; Jared R Radtke; Christiane S Hampe
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

Review 7.  The role of inflammation in the development of epilepsy.

Authors:  Amna Rana; Alberto E Musto
Journal:  J Neuroinflammation       Date:  2018-05-15       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.